| 论文作者 |
Li, YG; Tang, SJ; Shi, XH; Lv, JW; Wu, XY; Zhang, YH; Wang, H; He, J; Zhu, YQ; Ju, Y; Zhang, YJ; Guo, SW; Yang, WW; Yin, HY; Chen, LA; Gao, D; Jin, G |
| 摘要 |
Metabolic reprogramming is known as an emerging mechanism of chemotherapy resistance, but the meta-bolic signatures of pancreatic ductal adenocarcinomas (PDACs) remain unclear. Here, we characterize the metabolomic profile of PDAC organoids and classify them into glucomet-PDAC (high glucose metabolism levels) and lipomet-PDAC (high lipid metabolism levels). Glucomet-PDACs are more resistant to chemo-therapy than lipomet-PDACs, and patients with glucomet-PDAC have a worse prognosis. Integrated ana-lyses reveal that the GLUT1/aldolase B (ALDOB)/glucose-6-phosphate dehydrogenase (G6PD) axis induces chemotherapy resistance by remodeling glucose metabolism in glucomet-PDAC. Increased glycolytic flux, G6PD activity, and pyrimidine biosynthesis are identified in glucomet-PDAC with high GLUT1 and low ALDOB expression, and these phenotypes could be reversed by inhibiting GLUT1 expression or by increasing ALDOB expression. Pharmacological inhibition of GLUT1 or G6PD enhances the chemotherapy response of glucomet-PDAC. Our findings uncover potential metabolic heterogeneity related to differences in chemotherapy sensitivity in PDAC and develop a promising pharmacological strategy for patients with chemotherapy-resistant glucomet-PDAC through the combination of chemotherapy and GLUT1/ALDOB/ G6PD axis inhibitors. |
官方微信
